B-intervention	0	9	Tamoxifen
I-intervention	10	14	plus
I-intervention	15	22	tegafur
I-intervention	22	23	-
I-intervention	23	29	uracil
I-intervention	30	31	(
I-intervention	31	35	TUFT
I-intervention	35	36	)
O	37	43	versus
B-control	44	53	tamoxifen
I-control	54	58	plus
I-control	59	69	Adriamycin
I-control	70	71	(
I-control	71	82	doxorubicin
I-control	82	83	)
I-control	84	87	and
I-control	88	104	cyclophosphamide
I-control	105	106	(
I-control	106	109	ACT
I-control	109	110	)
O	111	113	as
O	114	122	adjuvant
O	123	130	therapy
O	131	133	to
O	134	139	treat
O	140	144	node
O	144	145	-
O	145	153	positive
O	154	167	premenopausal
O	168	174	breast
O	175	181	cancer
O	182	183	(
O	183	189	PreMBC
O	189	190	)
O	190	191	:
O	192	199	results
O	200	202	of
B-location	203	208	Japan
O	209	217	Clinical
O	218	226	Oncology
O	227	232	Group
O	233	238	Study
O	239	243	9404
O	243	244	.

O	245	246	A
O	247	258	prospective
O	259	269	randomized
O	270	278	clinical
O	279	284	trial
O	285	288	was
O	289	298	conducted
O	299	301	to
O	302	310	evaluate
O	311	314	the
O	315	323	efficacy
O	324	326	of
O	327	336	tamoxifen
O	337	341	plus
O	342	353	doxorubicin
O	354	357	and
O	358	374	cyclophosphamide
O	375	383	compared
O	384	386	to
O	387	396	tamoxifen
O	397	401	plus
O	402	409	tegafur
O	409	410	-
O	410	416	uracil
O	417	419	as
O	420	422	an
O	423	431	adjuvant
O	432	439	therapy
O	440	442	to
O	443	448	treat
O	449	453	node
O	453	454	-
O	454	462	positive
O	463	476	premenopausal
O	477	483	breast
O	484	490	cancer
O	491	492	(
O	492	498	PreMBC
O	498	499	)
O	499	500	.

O	501	512	Eligibility
O	513	521	criteria
O	522	530	included
B-eligibility	531	545	pathologically
I-eligibility	546	550	node
I-eligibility	550	551	-
I-eligibility	551	559	positive
I-eligibility	560	561	(
I-eligibility	561	562	n
I-eligibility	563	564	=
I-eligibility	565	566	1
I-eligibility	566	567	-
I-eligibility	567	568	9
I-eligibility	568	569	)
I-eligibility	570	576	preMBC
I-eligibility	577	581	with
I-eligibility	582	590	curative
I-eligibility	591	600	resection
I-eligibility	600	601	,
I-eligibility	602	604	in
I-eligibility	605	611	stages
I-eligibility	612	613	I
I-eligibility	613	614	-
I-eligibility	614	618	IIIA
O	618	619	.

O	620	628	Patients
O	629	633	were
O	634	644	randomized
O	645	647	to
O	648	655	receive
O	656	662	either
O	663	672	tamoxifen
O	673	675	20
O	676	678	mg
O	678	679	/
O	679	682	day
O	683	687	plus
O	688	695	tegafur
O	695	696	-
O	696	702	uracil
O	703	706	400
O	707	709	mg
O	709	710	/
O	710	713	day
O	714	715	(
O	715	717	TU
O	717	718	)
O	719	722	for
O	723	724	2
O	725	730	years
O	731	733	or
O	734	737	six
O	738	745	courses
O	746	748	of
O	749	750	a
O	751	753	28
O	753	754	-
O	754	757	day
O	758	763	cycle
O	764	766	of
O	767	778	doxorubicin
O	779	781	40
O	782	784	mg
O	784	785	/
O	785	786	m
O	786	787	(
O	787	788	2
O	788	789	)
O	790	794	plus
O	795	811	cyclophosphamide
O	812	815	500
O	816	818	mg
O	818	819	/
O	819	820	m
O	820	821	(
O	821	822	2
O	822	823	)
O	824	826	on
O	827	830	day
O	831	832	1
O	833	838	along
O	839	843	with
O	844	853	tamoxifen
O	854	855	(
O	855	858	ACT
O	858	859	)
O	860	865	given
O	866	869	for
O	870	871	2
O	872	877	years
O	878	880	as
O	881	889	adjuvant
O	890	897	therapy
O	897	898	.

O	899	906	Primary
O	907	915	endpoint
O	916	919	was
B-outcome-Measure	920	927	overall
I-outcome-Measure	928	936	survival
I-outcome-Measure	937	938	(
I-outcome-Measure	938	940	OS
I-outcome-Measure	940	941	)
O	941	942	,
O	943	946	and
O	947	956	secondary
O	957	965	endpoint
O	966	969	was
B-outcome-Measure	970	980	recurrence
I-outcome-Measure	980	981	-
I-outcome-Measure	981	985	free
I-outcome-Measure	986	994	survival
I-outcome-Measure	995	996	(
I-outcome-Measure	996	999	RFS
I-outcome-Measure	999	1000	)
O	1000	1001	.

O	1002	1004	In
O	1005	1010	total
O	1010	1011	,
B-total-participants	1012	1015	169
O	1016	1024	patients
O	1025	1029	were
O	1030	1039	recruited
O	1040	1041	(
O	1041	1043	TU
O	1044	1047	arm
B-intervention-participants	1048	1050	87
O	1050	1051	,
O	1052	1055	ACT
O	1056	1059	arm
B-control-participants	1060	1062	82
O	1062	1063	)
O	1064	1071	between
O	1072	1079	October
O	1080	1084	1994
O	1085	1088	and
O	1089	1098	September
O	1099	1103	1999
O	1103	1104	.

O	1105	1108	The
O	1109	1111	HR
O	1112	1115	for
B-outcome	1116	1118	OS
O	1119	1122	was
O	1123	1124	0
O	1124	1125	.
O	1125	1127	76
O	1128	1129	(
O	1129	1131	95
O	1132	1133	%
O	1134	1136	CI
O	1137	1138	0
O	1138	1139	.
O	1139	1141	35
O	1141	1142	,
O	1143	1144	1
O	1144	1145	.
O	1145	1147	66
O	1147	1148	,
O	1149	1152	log
O	1152	1153	-
O	1153	1157	rank
O	1158	1159	p
O	1160	1161	=
O	1162	1163	0
O	1163	1164	.
O	1164	1166	49
O	1166	1167	)
O	1168	1171	and
O	1172	1176	that
O	1177	1180	for
B-outcome	1181	1184	RFS
O	1185	1188	was
O	1189	1190	0
O	1190	1191	.
O	1191	1193	77
O	1194	1195	(
O	1195	1197	95
O	1198	1199	%
O	1200	1202	CI
O	1203	1204	0
O	1204	1205	.
O	1205	1207	44
O	1207	1208	,
O	1209	1210	1
O	1210	1211	.
O	1211	1213	36
O	1213	1214	,
O	1215	1218	log
O	1218	1219	-
O	1219	1223	rank
O	1224	1225	p
O	1226	1227	=
O	1228	1229	0
O	1229	1230	.
O	1230	1232	37
O	1232	1233	)
O	1233	1234	,
O	1235	1239	with
O	1240	1243	ACT
O	1244	1253	resulting
O	1254	1256	in
O	1257	1258	a
O	1259	1265	better
O	1266	1268	HR
O	1268	1269	.

O	1270	1273	The
B-outcome	1274	1275	5
I-outcome	1275	1276	-
I-outcome	1276	1280	year
I-outcome	1281	1283	OS
O	1284	1287	was
B-iv-bin-percent	1288	1290	79
I-iv-bin-percent	1290	1291	.
I-iv-bin-percent	1291	1292	7
I-iv-bin-percent	1293	1294	%
O	1295	1298	for
O	1299	1307	patients
O	1308	1310	in
O	1311	1314	the
O	1315	1317	TU
O	1318	1321	arm
O	1322	1325	and
B-cv-bin-percent	1326	1328	83
I-cv-bin-percent	1329	1330	%
O	1331	1334	for
O	1335	1340	those
O	1341	1343	in
O	1344	1347	the
O	1348	1351	ACT
O	1352	1355	arm
O	1355	1356	.

O	1357	1360	The
B-outcome	1361	1362	5
I-outcome	1362	1363	-
I-outcome	1363	1367	year
I-outcome	1368	1371	RFS
O	1372	1375	was
B-iv-bin-percent	1376	1378	66
I-iv-bin-percent	1378	1379	.
I-iv-bin-percent	1379	1380	1
I-iv-bin-percent	1381	1382	%
O	1383	1386	for
O	1387	1395	patients
O	1396	1398	in
O	1399	1402	the
O	1403	1405	TU
O	1406	1409	arm
O	1410	1413	and
B-cv-bin-percent	1414	1416	70
I-cv-bin-percent	1416	1417	.
I-cv-bin-percent	1417	1418	6
I-cv-bin-percent	1419	1420	%
O	1421	1424	for
O	1425	1430	those
O	1431	1433	in
O	1434	1437	the
O	1438	1441	ACT
O	1442	1445	arm
O	1445	1446	.

O	1447	1448	A
O	1449	1455	higher
O	1456	1466	proportion
O	1467	1469	of
O	1470	1478	patients
O	1479	1481	in
O	1482	1485	the
O	1486	1489	ACT
O	1490	1493	arm
O	1494	1505	experienced
B-outcome	1506	1511	grade
I-outcome	1512	1513	3
I-outcome	1514	1524	leucopenia
O	1525	1526	(
B-iv-bin-percent	1526	1527	0
I-iv-bin-percent	1528	1529	%
O	1530	1532	in
O	1533	1536	the
O	1537	1539	TU
O	1540	1543	arm
O	1543	1544	,
B-cv-bin-percent	1545	1546	4
I-cv-bin-percent	1547	1548	%
O	1549	1551	in
O	1552	1555	the
O	1556	1559	ACT
O	1560	1563	arm
O	1563	1564	)
O	1564	1565	.

O	1566	1571	There
O	1572	1576	were
O	1577	1579	no
O	1580	1591	significant
O	1592	1603	differences
O	1604	1606	in
O	1607	1610	the
O	1611	1619	efficacy
O	1620	1622	of
O	1623	1625	TU
O	1626	1629	and
O	1630	1633	ACT
O	1634	1636	as
O	1637	1645	adjuvant
O	1646	1653	therapy
O	1653	1654	.
